索拉非尼治疗后完全缓解肝癌患者&quot;等待观察&quot;策略安全性分析

doi:10.3877/cma.j.issn.2095-3232.2021.04.014

目的

探讨索拉非尼治疗后完全缓解的肝细胞癌（肝癌）患者采用"等待观察"策略的安全性和可行性。

方法

报道1例肝癌患者接受介入联合索拉非尼治疗达到完全病理缓解。患者已签署知情同意书，符合医学伦理学规定。检索2007年1月至2020年4月PubMed、Embase、Ovid、万方、中国知网、维普网等数据库收录的中英文临床研究文献。英文检索词："hepatocellular carcinoma"、"sorafenib"、"complete response"、"complete pathological response"。中文检索词："肝癌"、"索拉非尼"、"完全缓解"、"完全病理缓解"。统计以索拉非尼为基础治疗后完全缓解患者术后1、3、5年总体生存率和无进展生存率。生存分析采用Kaplan-Meier法和Log-rank检验。

结果

共纳入37篇文献，总计肝癌患者45例，其中男39例，女6例。患者术后1、3、5年总体生存率分别为100%、94.3%、94.3%，无进展生存率分别为100%、89.3%、89.3%。患者性别、年龄、AFP水平、BCLC分期、门静脉癌栓、肝外转移、病毒性肝炎情况、是否全量使用索拉非尼、治疗方案、是否行肝肿瘤切除、缓解情况等因素均不影响患者生存时间（χ²=0.260，1.411，0.219，0.852，0.087，1.838，0.916，1.065，0.539，0.027，0.590；P>0.05）及疾病复发（χ²=0.409，1.899，1.455，3.300，0.853，0.557，1.220，0.006，2.790，0.894，0.384；P>0.05 ）。

结论

以索拉非尼为基础治疗获完全缓解的肝癌患者生存预后明显改善，缓解后采用"等待观察"可能是一种安全有效的策略，不推荐进行肝癌切除或介入治疗。

关键词: 肝肿瘤, 索拉非尼, 完全缓解, 安全性

Objective

To evaluate the safety and feasibility of wait-and-see strategy for primary liver cancer (PLC) patients with complete response after sorafenib treatment.

Methods

1 case of PLC who achieved pathological complete response after interventional therapy combined with sorafenib therapy was reported. The informed consent of this patient was obtained and the local ethical committee approval was received. Relevant clinical studies were searched from PubMed, Embase, Ovid, Wanfang, CNKI and Chongqing VIP databases from January 2007 to April 2020 using the keywords hepatocellular carcinoma, sorafenib, complete response, complete pathological response in both Chinese and English. The 1-, 3- and 5-year overall survival and progression-free survival of PLC patients with complete response after sorafenib-based treatments were calculated. Survival analysis was conducted by Kaplan-Meier method and Log-rank test.

Results

37 articles of 45 PLC patients, 39 male and 6 female, were included. The 1-, 3-, and 5-year overall survival rates were 100%, 94.3%, and 94.3%, and the progression-free survival rates were 100%, 89.3%, and 89.3%, respectively. Gender, age, AFP level, BCLC staging, portal vein tumor thrombus, extrahepatic metastasis, viral hepatitis, use of full-dose sorafenib, therapeutic regimen, resection of liver tumor and condition of remission were not significantly associated with the survival of patients (χ²=0.260, 1.411, 0.219, 0.852, 0.087, 1.838, 0.916, 1.065, 0.539, 0.027, 0.590; P>0.05) and disease recurrence (χ²=0.409, 1.899, 1.455, 3.300, 0.853, 0.557, 1.220, 0.006, 2.790, 0.894, 0.384; P>0.05).

Conclusions

PLC patients who achieve complete response after sorafenib-based treatments can obtain favorable clinical prognosis. Application of wait-and-see strategy is a safe option. Liver tumor resection or interventional therapy is not recommended.

Key words: Liver neoplasms, Sorafenib, Complete remission, Safety

图1 一例以索拉非尼为基础治疗后完全缓解肝癌患者MRI及病理检查

表1 以索拉非尼为基础治疗后完全缓解肝癌患者基本信息

参数		例数	5年总体生存率（%）	χ²值	P值	5年无进展生存率（%）	χ²值	P值
性别				0.260	0.610		0.409	0.522
	男	39	93.6			87.4
	女	6	100			100
年龄（岁）				1.411	0.235		1.899	0.168
	>60	22	100			100
	≤60	23	90.4			82.2
AFP（μg/L）				0.219	0.64		1.455	0.228
	>400	29	96.0			82.5
	≤400	16	90.9			100
BCLC分期				0.852	0.653		3.300	0.192
	A期	11	100			75
	B期	3	100			100
	C期	31	92.0			92.9
门静脉癌栓				0.087	0.768		0.853	0.356
	有	24	95.0			90.9
	无	21	93.8			84.6
肝外转移				1.838	0.175		0.557	0.445
	有	10	85.7			100
	无	35	96.4			88.6
病毒性肝炎				0.916	0.339		1.220	0.269
	有	32	91.8			84.6
	无	13	100			100
全量服用索拉非尼				1.065	0.302		0.006	0.941
	是	16	100			91.7
	否	29	91.3			88.4
治疗方案				0.539	0.463		2.790	0.095
	索拉非尼+介入	13	90.9			77.8
	单药索拉非尼	19	95.8			99.3
肝肿瘤切除				0.027	0.870		0.894	0.334
	是	18	95.2			86.2
	否	27	92.9			92.3
缓解情况				0.590	0.442		0.384	0.535
	完全缓解	35	92.7			90.0
	完全病理缓解	10	100			87.5

表1 以索拉非尼为基础治疗后完全缓解肝癌患者基本信息

参数		例数	5年总体生存率（%）	χ²值	P值	5年无进展生存率（%）	χ²值	P值
性别				0.260	0.610		0.409	0.522
	男	39	93.6			87.4
	女	6	100			100
年龄（岁）				1.411	0.235		1.899	0.168
	>60	22	100			100
	≤60	23	90.4			82.2
AFP（μg/L）				0.219	0.64		1.455	0.228
	>400	29	96.0			82.5
	≤400	16	90.9			100
BCLC分期				0.852	0.653		3.300	0.192
	A期	11	100			75
	B期	3	100			100
	C期	31	92.0			92.9
门静脉癌栓				0.087	0.768		0.853	0.356
	有	24	95.0			90.9
	无	21	93.8			84.6
肝外转移				1.838	0.175		0.557	0.445
	有	10	85.7			100
	无	35	96.4			88.6
病毒性肝炎				0.916	0.339		1.220	0.269
	有	32	91.8			84.6
	无	13	100			100
全量服用索拉非尼				1.065	0.302		0.006	0.941
	是	16	100			91.7
	否	29	91.3			88.4
治疗方案				0.539	0.463		2.790	0.095
	索拉非尼+介入	13	90.9			77.8
	单药索拉非尼	19	95.8			99.3
肝肿瘤切除				0.027	0.870		0.894	0.334
	是	18	95.2			86.2
	否	27	92.9			92.3
缓解情况				0.590	0.442		0.384	0.535
	完全缓解	35	92.7			90.0
	完全病理缓解	10	100			87.5

图2 以索拉非尼为基础治疗后完全缓解肝癌患者Kaplan-Meier生存曲线

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2]	Kuzuya T, Ishigami M, Ito T, et al. Sorafenib vs. lenvatinib as first-line therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Anticancer Res, 2020, 40(4):2283-2290.
[3]	Zhang XP, Chai ZT, Gao YZ, et al. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis[J]. HPB, 2019, 21(12):1687-1696.
[4]	Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results[J]. Ann Surg, 2004, 240(4):711-717.
[5]	Willett CG. Management of locoregional rectal cancer[J]. J Natl Compr Canc Netw, 2018, 16(5S):617-619.
[6]	Abbadessa G, Rimassa L, Pressiani T, et al. Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib[J]. World J Gastroenterol, 2011, 17(19):2450-2453.
[7]	Ahn SY, Lee HS, Kweon YO, et al. Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy[J]. Dig Dis Sci, 2013, 58(5):1428-1432.
[8]	Atkin C, Earwaker P, Pallan A, et al. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature[J]. BMC Gastroenterol, 2017, 17(1):30.
[9]	Chaudhury PK, Hassanain M, Bouteaud JM, et al. Complete response of hepatocellular carcinoma with sorafenib and Y radioembolization[J]. Curr Oncol, 2010, 17(5):67-69.
[10]	Chelis L, Ntinos N, Souftas V, et al. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: possible synergy with HAART? a case report[J]. Med Oncol, 2011, 28 Suppl 1:S165-168.
[11]	Chen SC, Chao Y, Yang MH. Complete response to the combination of pembrolizumab and sorafenib for metastatic hepatocellular carcinoma: a case report[J]. Am J Gastroenterol, 2017, 112(4):659-660.
[12]	Curtit E, Thiery-Vuillemin A, Nguyen T, et al. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report[J]. J Clin Oncol, 2011, 29(12):e330-332.
[13]	de Stefano G, Iodice V, Farella N. Complete response to full-dose sorafenib treatment in an elderly HCC patient: a case report[J]. J Gastrointest Cancer, 2015, 46(4):430-433.
[14]	Elleuch N, Ennaifer R, Romdhane H, et al. Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma[J]. Tunis Med, 2015, 93(6):350-352.
[15]	Gamstätter T, Weinmann A, Schadmand-Fischer S, et al. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature[J]. Onkologie, 2011, 34(10):538-542.
[16]	Hagihara A, Teranishi Y, Kawamura E, et al. A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma[J]. Intern Med, 2013, 52(14):1589-1592.
[17]	Huan HB, Lau WY, Xia F, et al. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(39):14505-14509.
[18]	Inuzuka T, Nishikawa H, Sekikawa A, et al. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report[J]. Oncology, 2011, 81 Suppl 1: 152-157.
[19]	Irtan S, Chopin-Laly X, Ronot M, et al. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection[J]. Liver Int, 2011, 31(5):740-743.
[20]	Kee KM, Hung CH, Wang JH, et al. Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib[J]. Onco Targets Ther, 2014(7):829-834.
[21]	Kermiche-Rahali S, Di Fiore A, Drieux F, et al. Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib[J]. World J Surg Oncol, 2013, 11(1):171.
[22]	Kim DH, Cho E, Cho SB, et al. Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): a case report and literature review[J]. Medicine, 2018, 97(42):e12866.
[23]	Kim MS, Jin YJ, Lee JW, et al. Complete remission of advanced hepatocellular carcinoma by sorafenib: a case report[J]. World J Gastrointest Oncol, 2013, 5(2):38-42.
[24]	Kim TS, Kim JH, Kim BH, et al. Complete response of advanced hepatocellular carcinoma to sorafenib: another case anda comprehensive review[J]. Clin Mol Hepatol, 2017, 23(4):340-346.
[25]	Kim Y, Hosoda Y, Kakita N, et al. A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration[J]. Gan To Kagaku Ryoho, 2014, 41(12):2124-2126.
[26]	Kirstein MM, Schweitzer N, Schmidt S, et al. Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma[J]. Acta Gastroenterol Belg, 2014, 77(4):386-388.
[27]	Kitajima T, Hatano E, Mitsunori Y, et al. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection[J]. Clin J Gastroenterol, 2015, 8(5):300-305.
[28]	Lee HY, Yang KH, Choi BH, et al. Complete regression of recurrent advanced hepatocellular carcinoma after liver transplantation in response to sorafenib treatment: a case report[J]. Transplant Proc, 2016, 48(1):247-250.
[29]	Liu D, Liu A, Peng J, et al. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib[J]. Eur J Med Res, 2015, 20(1):12.
[30]	Lorenzin D, Pravisani R, Leo CA, et al. Complete remission of unresectable hepatocellular carcinoma after combined sorafenib and adjuvant Yttrium-90 radioembolization[J]. Cancer Biother Radiopharm, 2016, 31(2):65-69.
[31]	Maida M, Macaluso FS, Valenza F, et al. Complete and sustained off-therapy response to sorafenib in advanced hepatocellular carcinoma[J]. J Gastrointestin Liver Dis, 2016, 25(2):253-255.
[32]	Mizukami H, Kagawa T, Arase Y, et al. Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma[J]. Case Rep Oncol, 2012, 5(2):380-384.
[33]	Moroni M, Zanlorenzi L. Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma[J]. Future Oncol, 2013, 9(8):1231-1237.
[34]	Poullenot F, Bioulac-Sage P, Laumonier H, et al. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? about four cases[J]. Acta Oncol, 2014, 53(3):420-423.
[35]	Sacco R, Bargellini I, Gianluigi G, et al. Complete response for advanced liver cancer during sorafenib therapy: case report[J]. BMC Gastroenterol, 2011(11):4.
[36]	Shinoda M, Kishida N, Itano O, et al. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature[J]. World J Surg Oncol, 2015(13):144.
[37]	Shiozawa K, Watanabe M, Ikehara T, et al. Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: a case report[J]. Oncol Lett, 2014, 7(1):50-52.
[38]	Simão A, Silva R, Correia L, et al. Advanced stage hepatocellular carcinoma with multiple metastasis and vascular thrombosis: a case of complete response to sorafenib[J]. Acta Med Port, 2016, 29(2):139-142.
[39]	So BJ, Bekaii-Saab T, Bloomston MA, et al. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report[J]. J Hematol Oncol, 2008(1):18.
[40]	Takano M, Kokudo T, Miyazaki Y, et al. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(42):9445-9450.
[41]	Waidmann O, Peveling-Oberhag J, Eichler K, et al. To treat or not to treat-successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenib[J]. Z Gastroenterol, 2017, 55(6):564-568.
[42]	Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib[J]. Am J Transplant, 2009, 9(12):2851-2854.
[43]	Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66(24):11851-11858.
[44]	Nakagawa WT, Rossi BM, de O Ferreira F, et al. Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe?[J]. Ann Surg Oncol, 2002, 9(6):568-573.
[45]	Glynne-Jones R, Hughes R. Critical appraisal of the 'wait and see' approach in rectal cancer for clinical complete responders after chemoradiation[J]. Br J Surg, 2012, 99(7):897-909.
[46]	Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy[J]. J Gastrointest Surg, 2006, 10(10):1319-1328.
[47]	Kim HJ, Song JH, Ahn HS, et al. Wait and see approach for rectal cancer with a clinically complete response after neoadjuvant concurrent chemoradiotherapy[J]. Int J Colorectal Dis, 2017, 32(5): 723-727.

[1]	洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 571-579.
[2]	王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[3]	高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[4]	朴成林, 蓝炘, 司振铎, 李强, 冯健, 安峰铎, 冷建军. 胰十二指肠切除联合肝切除术疗效分析：附5例报告（附视频）[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 363-367.
[5]	常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[6]	赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[7]	王浩源, 汪海洋, 孙建明, 陈以宽, 祁小桐, 唐博. 腹腔镜与开放修补对肝硬化腹外疝患者肝功能及凝血的影响[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 654-659.
[8]	王鹏, 邵欣欣, 胡海涛, 田艳涛, 钟宇新. 改良MOBS 吻合法在全腹腔镜近端胃大部分切除中的应用[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 267-270.
[9]	李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[10]	陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[11]	吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[12]	林小勇, 张兰霞, 曾庆劲, 贺需旗, 谭雷, 郭光辉, 龙颖琳, 李凯, 吴宇轩. 负压抽吸活检针在肝困难病灶活检中的初步应用研究[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 694-698.
[13]	雷永琪, 刘新阳, 杨黎渝, 铁学宏, 俞星新, 耿志达, 刘雨, 陈政良, 惠鹏, 梁英健. 肝脏血管周上皮样细胞肿瘤合并贫血一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 710-718.
[14]	王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15]	张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Safety of wait-and-see strategy for primary liver cancer patients with complete response after sorafenib treatment

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Safety of wait-and-see strategy for primary liver cancer patients with complete response after sorafenib treatment